» Articles » PMID: 29556302

Tumor Suppressor Candidate 3: A Novel Grading Tool and Predictor of Clinical Malignancy in Human Gliomas

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Mar 21
PMID 29556302
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

For several years, the cause of autosomal recessive mental retardation has been attributed to the deletion or mutation of a gene named tumor suppressor candidate 3 (TUSC3). Previous research has identified that TUSC3 is a potential tumor suppressor gene in oral epidermoid carcinoma, lung cancer and esophageal cancer. However, to the best of our knowledge, no previously published data has existed on the expression of TUSC3 in gliomas. The present study focused on the expression of TUSC3 in brain gliomas. Additionally, the present study sought to identify he association between TUSC3 expression and the typical clinical and pathological disease manifestations of gliomas. TUSC3 levels were evaluated using a western blot assay and immunohistochemistry on tissue microarray slides. Results indicated a significant decrease in TUSC3 expression in glioma tissues compared with the normal adjacent tissues. Furthermore, TUSC3 expression and World Health Organization grade demonstrated an inverse association in patients with glioma. This revealed that lower levels of TUSC3 in gliomas may be associated with a poorly-differentiated (high grade) tumor and thus a higher malignancy. Through the combination of the results of the present study and future research projects, TUSC3 may be a novel grading tool that assists with evaluating tumor malignancy and consequently a more active therapeutic regimen may be used in patients with glioma.

Citing Articles

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.

Wu Q, Berglund A, Macaulay R, Etame A Int J Mol Sci. 2023; 24(20).

PMID: 37894860 PMC: 10606804. DOI: 10.3390/ijms242015179.


Genome-Wide Identification of Cis-acting Expression QTLs in Large Yellow Croaker.

Jiang D, Li W, Wang Z, Fang M Mar Biotechnol (NY). 2021; 23(2):225-232.

PMID: 33507423 DOI: 10.1007/s10126-020-10017-0.


Downregulation of microRNA-320a inhibits proliferation and induces apoptosis of retinoblastoma cells via targeting TUSC3.

Kong L, Sun Y, Chen M, Dai Y, Liu Z Exp Ther Med. 2020; 20(5):9.

PMID: 32934674 PMC: 7471862. DOI: 10.3892/etm.2020.9137.


Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival.

Granados-Soler J, Bornemann-Kolatzki K, Beck J, Brenig B, Schutz E, Betz D Sci Rep. 2020; 10(1):1003.

PMID: 31969654 PMC: 6976565. DOI: 10.1038/s41598-020-57942-7.

References
1.
Mohorko E, Glockshuber R, Aebi M . Oligosaccharyltransferase: the central enzyme of N-linked protein glycosylation. J Inherit Metab Dis. 2011; 34(4):869-78. DOI: 10.1007/s10545-011-9337-1. View

2.
Horak P, Tomasich E, Vanhara P, Kratochvilova K, Anees M, Marhold M . TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo. Sci Rep. 2014; 4:3739. PMC: 3894551. DOI: 10.1038/srep03739. View

3.
Walsh K, Ohgaki H, Wrensch M . Epidemiology. Handb Clin Neurol. 2016; 134:3-18. DOI: 10.1016/B978-0-12-802997-8.00001-3. View

4.
Khan M, Rafiq M, Noor A, Ali N, Ali G, Vincent J . A novel deletion mutation in the TUSC3 gene in a consanguineous Pakistani family with autosomal recessive nonsyndromic intellectual disability. BMC Med Genet. 2011; 12:56. PMC: 3096909. DOI: 10.1186/1471-2350-12-56. View

5.
Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak T . The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell. 2010; 143(5):711-24. DOI: 10.1016/j.cell.2010.10.010. View